Human Insulin Market Research Report - Global Forecast till 2027

Human Insulin Market: Information by Type (Traditional Human Insulin (Premixed Traditional, Intermediate Acting and Short-Acting), Modern Human Insulin (Premixed Modern, Long-Acting and Rapid Acting) and Brand (Lantus, Novorapid, Humalog, Novomix, Levemir, Apidar, Humulin and Insuman)) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast till 2027

ID: MRFR/Pharma/0445-CR | February 2021 | Region: Global | 117 pages

Global Human Insulin Market is expected to grow at CAGR of 12.10% to reach USD 90,812.40 Million till 2025. Human insulin in the report refers to synthetic insulin manufactured in laboratories by increasing insulin protein with the help of e. coli bacteria. Human insulin can be administered orally or through insulin infusion devices. Some conventional insulin infusion devices are syringes, injection pens, and insulin pumps. These devices are used to deliver insulin on time and regularly.


Increasing prevalence of diabetes, rising obesity endemic, rise in geriatric population, and increasing awareness among people about diabetic care and technological advancement in delivery devices of insulin are some of the factors influencing the growth of the human insulin market. However, strict regulatory requirements for approval of insulin and high cost of insulin analog inhibit the growth of the human insulin market.


Market Dynamics


The increasing affordability of human insulin is one of the key factors driving the human insulin market. In May 2019, Eli Lilly and Company launched Insulin Lispro Injection for people who use Lilly's rapid-acting insulin and need a lower-cost option. Insulin Lispro Injection has a 50% lower price than its identical medicine, Humalog U-100 (insulin lispro injection).


Increasing diabetic population is also strongly impacting the growth of the market. Diabetes is a chronic and non-communicable disease, and its global prevalence is rising enormously. Nowadays, it is one of the leading causes of death and has an increased risk of developing several serious health problems. It is the primary cause of cardiovascular diseases, kidney diseases, eye disorders, and strokes.


As per 2017, National Diabetes Statistic Report suggested by the Centers for Disease Control and Prevention, more than 100 million people in the US have diabetes or prediabetes.


Global Human Insulin Market Revenue, by Traditional Human Insulin, 2018 (%)  Human Insulin Market


Sources: MRFR Analysis


Segmentation


Based on type, the global human insulin market has been segmented into traditional human insulin and modern human insulin. Traditional human insulin segment includes premixed traditional, intermediate-acting, and short-acting. Modern human insulin segment includes premixed modern, long-acting, and rapid-acting. Modern human insulin was the leading segment in 2018. Modern human insulin, also known as analog insulin, is prescribed by physicians for the treatment of diabetes. It is the customized form of traditional human insulin and provides effective results in comparison to traditional human insulin.


The global human insulin market, by brand, has been segmented into Lantus, Novorapid, Humalog, Novomix, Levemir, Apidar, Humulin, and Insuman. Lantus is a long-acting human insulin analog, and it is available in more than 120 countries. Among all the brands, Lantus commands the largest share in the human insulin market. Apidra is a rapid acting human insulin analog. Also, Apidra and Levemir are the fastest growing brand in the human insulin market. Moreover, there are various drugs in the pipeline, which would have a positive impact on the growth of the market in the coming years.


Global Human Insulin Market Share, by Region, 2018 (%)  Human Insulin Market


Sources: MRFR Analysis


Regional Analysis


The global human insulin market has been categorized as the Americas, Europe, Asia-Pacific, and Middle East & Africa.


The Americas dominate the global human insulin market, owing to the growing old age population, increasing healthcare awareness, rising prevalence of diabetes, improvement in reimbursement policies, and increasing clinical trials driving the growth of human insulin.


The European Human Insulin market has been segmented into Western Europe and Eastern Europe. In 2018, Europe stood second in the global Human Insulin market. Increasing focus on the treatment of diabetes and rising clinical trials by market players will support the growth of Europe Human Insulin market. For instance, a France-based firm, Adocia received positive topline pharmacodynamic and safety results from the first Phase 1 study of ADO09. ADO09 is intended to improve postprandial glucose control and long-term outcomes for people requiring prandial insulin treatment.


Asia-Pacific is expected to register the highest CAGR during the forecast period. Companies are introducing new advanced products in this region, which is boosting Asia-Pacific human insulin market. In March 2018, Biocon Ltd and Mylan NV received approval for biosimilar insulin glargine Semglee 100 IU/mL 3 mL prefilled pen from the Therapeutic Goods Administration (TGA) Australia.


On the other hand, the Middle East & Africa holds the least share in the global human insulin market due to the low economic development, especially within the African region.


Key Players


The prominent players in the global human insulin market are ADOCIA, MERCK & CO., INC., Julphar, Pfizer Inc., Bristol-Myers Squibb Company, GLAXOSMITHKLINE PLC, SANOFI, Oramed, Novo Nordisk India Pvt. Ltd, Eli Lilly and Company, BIOCON, and Tonghua Dongbao Pharmaceutical Co., Ltd.


Some of the key strategies followed by the players operating in the global human insulin market were innovation, product development, acquisition, and expansion.



  • In August 2018, Novo Nordisk acquired all the shares of Ziylo. Through this acquisition, Novo Nordisk gained full rights to Ziylo's glucose binding molecule platform to develop glucose responsive insulins (GRIs). This is a critical strategic area for Novo Nordisk in its effort to develop this next generation of insulin, which would lead to safer and more effective insulin therapy.



  • In April 2015, Biocon announced that its Insulin Glargine has been approved by COFEPRIS, the Mexican health authority, through its partner PiSAFarmaceutica (PiSA) and has strengthened its position in Mexico.


Market Segmentation


Global Human Insulin Market, by Type



  • Traditional Human Insulin

    • Premixed Traditional

    • Intermediate Acting

    • Short-Acting





  • Modern Human Insulin

    • Premixed Modern

    • Long-Acting

    • Rapid Acting




Global Human Insulin Market, by Brand



  • Lantus

  • Novorapid

  • Humalog

  • Novomix

  • Levemir

  • Apidar

  • Humulin

  • Insurance


Global Human Insulin Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • UK

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • Australia

    • India

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Pharmaceuticals manufacturers and suppliers

  • Medical research laboratories

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Potential investors



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 90,812.40 Million
  • 2027: Significant Value
  •   CAGR   12.10% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Modern Human Insulin and Brand
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   ADOCIA, MERCK & CO., INC., Julphar, Pfizer Inc., Bristol-Myers Squibb Company, GLAXOSMITHKLINE PLC, SANOFI, Oramed, Novo Nordisk India Pvt. Ltd, Eli Lilly and Company, BIOCON, and Tonghua Dongbao Pharmaceutical Co., Ltd.
      Key Market Opportunities   increasing affordability of human insulin
      Key Market Drivers

  • Increasing prevalence of diabetes
  • rising obesity endemic
  • rise in geriatric population
  • increasing awareness among people


  • Frequently Asked Questions (FAQ) :


    Global Human Insulin Market is expected to accumulate revenues at a CAGR of 12.1% from 2020 to 2027.

    Global Human Insulin Market is driven by the large prevalence of diabetes mellitus.

    The large geriatric populace affected by diabetes and diabetes management are two of the secondary drivers which can fuel the Global Human Insulin Market.

    The Americas holds the largest share of the Global Human Insulin Market.

    Europe holds the second-largest share of the Global Human Insulin Market owing to heavy funds in research of diabetes.

    Oramed Pharmaceuticals, Inc., ADOCIA, Julphar, Novo Nordisk A/S, Bristol-Myers Squibb Company, Tonghua Dongbao Pharmaceuticals Co., Ltd., Biocon Ltd, Merck & Co, GlaxoSmithKline, Sanofi, and Pfizer, Inc. are major players of the Global Human Insulin Market.

    1 Report Prologue

    2 Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3 Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    4 Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Macroeconomic Indicators

    4.5 Trends & Assessment

    5 Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Opportunities

    6 Human Insulin Market, by Type

    6.1 Introduction

    6.2 Traditional Human Insulin

    6.2.1 Premixed Traditional

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.2.2 Intermediate Acting

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.2.3 Short Acting

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Modern Human Insulin

    6.3.1 Premixed Modern

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.2 Long Acting

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3.3 Rapid Acting

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7 Human Insulin Market, by Brand

    7.1 Introduction

    7.2 Lantus

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.3 Novorapid

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.4 Humalog

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.5 Novomix

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.6 Levemir

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.7 Apidar

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.8 Humulin

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.9 Insuman

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8 Global Human Insulin Market, by Region

    8.1 Introduction

    8.2 Americas

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.2.1 North America

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.2.1.1 US

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.2.1.2 Canada

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.2.2 South America

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.3 Europe

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.3.1 Western Europe

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.3.1.1 Germany

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.3.1.2 France

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.3.1.3 Italy

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.3.1.4 Spain

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.3.1.5 UK

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.3.1.6 Rest of Western Europe

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.3.2 Eastern Europe

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.4 Asia-Pacific

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.4.1 Japan

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.4.2 China

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.4.3 India

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.4.4 Australia

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.4.5 South Korea

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.4.6 Rest of Asia-Pacific

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.5 Middle East & Africa

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.5.1 Middle East

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    8.5.2 Africa

    Human Insulin Market, by Type

    Human Insulin Market, by Brand

    9 Company Landscape

    9.1 Introduction

    9.2 Market Share Analysis

    9.3 Key Development & Strategies

    10 Company Profiles

    10.1 ADOCIA

    10.1.1 Company Overview

    10.1.2 Product Overview

    10.1.3 Financials Overview

    10.1.4 Key Developments

    10.1.5 SWOT Analysis

    10.2 MERCK & CO., INC.

    10.2.1 Company Overview

    10.2.2 Product Overview

    10.2.3 Financial Overview

    10.2.4 Key Developments

    10.2.5 SWOT Analysis

    10.3 Julphar

    10.3.1 Company Overview

    10.3.2 Product Overview

    10.3.3 Financial Overview

    10.3.4 Key Development

    10.3.5 SWOT Analysis

    10.4 Pfizer Inc.

    10.4.1 Company Overview

    10.4.2 Product Overview

    10.4.3 Financial Overview

    10.4.4 Key Development

    10.4.5 SWOT Analysis

    10.5 Bristol-Myers Squibb Company

    10.5.1 Company Overview

    10.5.2 Product Overview

    10.5.3 Financial overview

    10.5.4 Key Developments

    10.5.5 SWOT Analysis

    10.6 GLAXOSMITHKLINE PLC

    10.6.1 Company Overview

    10.6.2 Product Overview

    10.6.3 Financial Overview

    10.6.4 Key Developments

    10.6.5 SWOT Analysis

    10.7 SANOFI

    10.7.1 Overview

    10.7.2 Product Overview

    10.7.3 Financials

    10.7.4 Key Developments

    10.7.5 SWOT Analysis

    10.8 Oramed

    10.8.1 Overview

    10.8.2 Product Overview

    10.8.3 Financials

    10.8.4 Key Developments

    10.8.5 SWOT Analysis

    10.9 Novo Nordisk India Pvt. Ltd

    10.9.1 Overview

    10.9.2 Product Overview

    10.9.3 Financials

    10.9.4 Key Developments

    10.9.5 SWOT Analysis

    10.10 Eli Lilly and Company

    10.10.1 Overview

    10.10.2 Product Overview

    10.10.3 Financials

    10.10.4 Key Developments

    10.10.5 SWOT Analysis

    10.11 BIOCON

    10.11.1 Overview

    10.11.2 Product Overview

    10.11.3 Financials

    10.11.4 Key Developments

    10.11.5 SWOT Analysis

    10.12 Tonghua Dongbao Pharmaceutical Co., Ltd

    10.12.1 Overview

    10.12.2 Product Overview

    10.12.3 Financials

    10.12.4 Key Developments

    10.12.5 SWOT Analysis

    10.13 Others

    11 MRFR Conclusion

    11.1 Key Findings

    11.1.1 From CEO’s Viewpoint

    11.1.2 Unmet Needs of the Market

    11.2 Key Companies to Watch

    11.3 Predictions for the global Human Insulin market

    12 Appendix

    13 LIST OF TABLES

    Table 1 Human Insulin Market Synopsis, 2020–2027

    Table 2 Human Insulin Market Estimates and Forecast, 2020–2027 (USD Million)

    Table 3 Global Human Insulin Market, by Region, 2020–2027 (USD Million)

    Table 4 Global Human Insulin Market, by Type, 2020–2027 (USD Million)

    Table 5 Global Human Insulin Market, by Brand, 2020–2027 (USD Million)

    Table 6 North America: Human Insulin Market, by Type, 2020–2027 (USD Million)

    Table 7 North America: Human Insulin Market, by Brand, 2020–2027 (USD Million)

    Table 8 US: Human Insulin Market, by Type, 2020–2027 (USD Million)

    Table 9 US: Human Insulin Market, by Brand, 2020–2027 (USD Million)

    Table 10 Canada: Human Insulin Market, by Type, 2020–2027 (USD Million)

    Table 11 Canada: Human Insulin Market, by Brand, 2020–2027 (USD Million)

    Table 12 South America: Human Insulin Market, by Type, 2020–2027 (USD Million)

    Table 13 South America: Human Insulin Market, by Brand, 2020–2027 (USD Million)

    Table 14 Europe: Human Insulin Market, by Type, 2020–2027 (USD Million)

    Table 15 Europe: Human Insulin Market, by Brand, 2020–2027 (USD Million)

    Table 16 Western Europe: Human Insulin Market, by Type, 2020–2027 (USD Million)

    Table 17 Western Europe: Human Insulin Market, by Brand, 2020–2027 (USD Million)

    Table 18 Eastern Europe: Human Insulin Market, by Type, 2020–2027 (USD Million)

    Table 19 Eastern Europe: Human Insulin Market, by Brand, 2020–2027 (USD Million)

    Table 20 Asia-Pacific: Human Insulin Market, by Type, 2020–2027 (USD Million)

    Table 21 Asia-Pacific: Human Insulin Market, by Brand, 2020–2027 (USD Million)

    Table 22 Middle East & Africa: Human Insulin Market, by Type, 2020–2027 (USD Million)

    Table 23 Middle East & Africa: Human Insulin Market, by Brand, 2020–2027 (USD Million)

    14 LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Human Insulin Market

    Figure 3 Market Dynamics for Global Human Insulin Market

    Figure 4 Human Insulin Market Share, by Type, 2020

    Figure 5 Human Insulin Market Share, by Brand, 2020

    Figure 6 Human Insulin Market Share, by Region, 2020

    Figure 7 North America: Human Insulin Market Share, by Country, 2020

    Figure 8 Europe: Human Insulin Market Share, by Country, 2020

    Figure 9 Asia-Pacific: Human Insulin Market Share, by Country, 2020

    Figure 10 Middle East & Africa: Human Insulin Market Share, by Region, 2020

    Figure 11 Human Insulin Market: Company Share Analysis, 2020 (%)

    Figure 12 ADOCIA: Key Financials

    Figure 13 ADOCIA: Segmental Revenue

    Figure 14 ADOCIA: Geographical Revenue

    Figure 15 MERCK & CO., INC.: Key Financials

    Figure 16 MERCK & CO., INC.: Segmental Revenue

    Figure 17 MERCK & CO., INC.: Geographical Revenue

    Figure 18 Julphar: Key Financials

    Figure 19 Julphar: Segmental Revenue

    Figure 20 Julphar: Geographical Revenue

    Figure 21 Pfizer Inc.: Key Financials

    Figure 22 Pfizer Inc.: Segmental Revenue

    Figure 23 Pfizer Inc.: Geographical Revenue

    Figure 24 Bristol-Myers Squibb Company: Key Financials

    Figure 25 Bristol-Myers Squibb Company: Segmental Revenue

    Figure 26 Bristol-Myers Squibb Company: Geographical Revenue

    Figure 27 GLAXOSMITHKLINE PLC: Key Financials

    Figure 28 GLAXOSMITHKLINE PLC: Segmental Revenue

    Figure 29 GLAXOSMITHKLINE PLC: Geographical Revenue

    Figure 30 Oramed: Key Financials

    Figure 31 Oramed: Segmental Revenue

    Figure 32 Oramed: Geographical Revenue

    Figure 33 Novo Nordisk India Pvt Ltd: Key Financials

    Figure 34 Novo Nordisk India Pvt Ltd: Segmental Revenue

    Figure 35 Novo Nordisk India Pvt Ltd: Geographical Revenue

    Figure 36 Eli Lilly and Company: Key Financials

    Figure 37 Eli Lilly and Company: Segmental Revenue

    Figure 38 Eli Lilly and Company: Geographical Revenue

    Figure 39 SANOFI: Key Financials

    Figure 40 SANOFI: Segmental Revenue

    Figure 41 SANOFI: Geographical Revenue

    Figure 42 BIOCON: Key Financials

    Figure 43 BIOCON: Segmental Revenue

    Figure 44 BIOCON: Geographical Revenue

    Figure 45 Tonghua Dongbao Pharmaceutical Co., Ltd.: Key Financials

    Figure 46 Tonghua Dongbao Pharmaceutical Co., Ltd.: Segmental Revenue

    Figure 47 Tonghua Dongbao Pharmaceutical Co., Ltd.: Geographical Revenue